GLP-1 weight loss medications, popular in human health, may soon be available for pets as veterinarians search for new ways to combat rising obesity rates in cats. A new clinical study called MEOW-1 is testing whether a long-acting GLP-1 implant can safely support weight loss and improve overall health in overweight felines.
New GLP-1 Implant Designed for Cat Weight Management
San Francisco–based Okava Pharmaceuticals has launched a trial involving 50 cats, using a small under-the-skin implant known as OKV-119. The device slowly releases a GLP-1 medication over six months, reducing the need for daily injections or changes in feeding routines.
According to the company, the implant is designed to mimic the effects of fasting — improving insulin sensitivity, decreasing fat mass, and helping the body use energy more efficiently. The goal is to support healthy weight loss while preserving the strong human-pet bond, especially since feeding is a major part of daily interaction.
Rising Pet Obesity Creates Demand for New Treatments
Experts estimate that nearly 60% of cats in the United States are overweight. Veterinarians say traditional advice — “eat less and move more” — is often ineffective, especially for cats prone to metabolic disorders.
Pet obesity specialist Dr. Ernie Ward notes that GLP-1 treatments could provide benefits beyond weight loss, such as improved diabetes risk and long-term metabolic health. However, he says key questions remain regarding the drug’s effectiveness, potential side effects, and final pricing.
Expected Cost and Owner Interest
Okava aims to offer the treatment for about $100 per month, making it potentially accessible for pet owners seeking medical solutions for weight management.
Many cat owners say they would consider the treatment if recommended by their veterinarian. One owner of a 21-pound senior cat shared that she would strongly consider the therapy if her pet developed diabetes or if other weight-loss interventions failed.
When Will GLP-1 for Pets Be Available?
Initial results from the MEOW-1 study are expected next summer. If successful, Okava plans to seek FDA approval within the next two years. A similar version for dogs is already in development.
As pet obesity continues to rise, GLP-1 treatments may represent a new era in veterinary weight-management solutions, offering hope for healthier, longer-living cats and dogs.
Leave a Reply